Overview

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and tolerability of single and multiple subcutaneous (SC) doses of JNJ-75220795.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC